Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Mar 25, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding new ways to diagnose lung cancer at an early stage. Researchers are studying breath, urine, and blood samples from 200 participants—half of whom have early-stage lung cancer and half who are healthy. The goal is to identify specific markers (called "omics" biomarkers) that can help tell the difference between someone with early lung cancer and someone who is healthy. By using advanced technologies, the team hopes to discover valuable information that could improve diagnosis and treatment in the future.
To be eligible for the trial, participants must be either diagnosed with early-stage lung cancer or considered at high risk for lung cancer, such as heavy smokers or individuals with a family history of the disease. It's important that healthy participants have had a recent negative chest X-ray or CT scan. Throughout the study, participants will provide samples before any surgical treatment for lung cancer and will be asked about their health history. The findings from this research could lead to better methods for early detection of lung cancer, which is crucial for improving treatment outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Lung cancer group
- • Diagnosis of early stage - lung cancer
- • Signed Informed Consent
- • Completed questionnaire
- • 2. Healthy subjects
- • high risk individuals (heavy smokers, subjects with pulmonary disease non-cancer related or with a familiar history of lung cancer disease)
- • Recent (within 6 months) negative Chest X-ray or CT scan
- Exclusion Criteria:
- • Both groups
- • No previous chemo or radiotherapy for lung cancer
- • No previous malignancies within last 5 years
- • No abuse of alcohol (no more than 1 litre of wine for day).
- • No patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study
About European Institute Of Oncology
The European Institute of Oncology (IEO) is a leading research and treatment center based in Milan, Italy, dedicated to advancing cancer care through innovative clinical research and personalized medicine. Renowned for its commitment to multidisciplinary approaches, IEO integrates cutting-edge research with clinical practice to improve patient outcomes. The institute actively sponsors and conducts clinical trials across various cancer types, fostering collaboration between oncologists, researchers, and industry partners. With a focus on translating scientific discoveries into effective therapies, IEO plays a pivotal role in the global fight against cancer, contributing to the development of new treatment protocols and enhancing the understanding of oncological diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported